Clinical study of tirofiban in non-invasive treatment for acute ST-segment elevation myocardial infarction

Objective:To investigate the application efficacy and safety of platelet membrane glycoprotein(GP) Ⅱb/Ⅲa receptor antagonist tirofiban hydrochloride in non-invasive treatment for ST-segment elevation myocardial infarction.Method:Patients(n=133) with acute ST-segment elevation myocardial infarction between August 2005 and April 2009 were selected and divided into tirofiban group and control group randomly according to the order of hospitalization.Compared basic clinical circumstances,major adverse cardiovascular events(MACE) in 48 hours and 30-day period,daily consumption of nitroglycerin,left ventricular ejection fraction(LEVF) in 30 days after myocardial infarction,bleeding events,platelet count and platelet aggregation rate of two groups.Result:Basic clinical situation,bleeding events,platelet count of two groups had no significance(P0.05).Compared with the control group,the incidence of angina pectoris,reinfarction,death and platelet aggregation rate in tirofiban group was significantly lower(P0.05).Daily consumption of nitroglycerin of tirofiban group significantly reduced compared with control group(P0.01).LEVF in 30 days after myocardial infarction was higher than that of control group,but no statistical significance(P0.05).Conclusion:The combination domestic tirofiban hydrochloride and the standard treatment ST-segment elevation myocardial infarction could significantly reduce MACE after acute myocardial infarction and daily consumption of nitroglycerin,improve LEVF,decrease platelet aggregation rate in acute ST-segment elevation myocardial infarction patients with non-invasive treatment,and does not increase the risk of bleeding.